Harnessing Therapeutic IgE Antibodies to Re-educate Macrophages against Cancer.
AllergoOncology
FcεRI
IgE
cancer
cancer immunotherapy
macrophages
monocytes
tumor-associated macrophage
Journal
Trends in molecular medicine
ISSN: 1471-499X
Titre abrégé: Trends Mol Med
Pays: England
ID NLM: 100966035
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
31
10
2019
revised:
05
03
2020
accepted:
09
03
2020
entrez:
30
5
2020
pubmed:
30
5
2020
medline:
9
7
2021
Statut:
ppublish
Résumé
Currently, IgG is the only class of antibodies employed for cancer therapy. However, harnessing the unique biological properties of a different class ( e.g., IgE) could engender potent effector cell activation, and unleash previously untapped immune mechanisms against cancer. IgE antibodies are best known for pathogenic roles in allergic diseases and for protective effector functions against parasitic infestation, often mediated by IgE Fc receptor-expressing macrophages. Notably, IgE possess a very high affinity for cognate Fc receptors expressed by tumor-associated macrophages (TAMs). This paper reviews pre-clinical studies, which indicate control of cancer growth by tumor antigen-specific IgE that recruit and re-educate TAMs towards activated profiles. The clinical development harnessing the antitumor potential of recombinant IgE antibodies in cancer patients is also discussed.
Identifiants
pubmed: 32470387
pii: S1471-4914(20)30067-8
doi: 10.1016/j.molmed.2020.03.002
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Receptors, Fc
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
615-626Subventions
Organisme : Medical Research Council
ID : MR/L023091/1
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.